Literature DB >> 1659596

The pathogenicity of ribonucleotide reductase-null mutants of herpes simplex virus type 1 in mice.

Y Yamada1, H Kimura, T Morishima, T Daikoku, K Maeno, Y Nishiyama.   

Abstract

The pathogenicity of ribonucleotide reductase (RR)-null mutants (hrR3 and ICP6 delta) of herpes simplex virus (HSV) type 1 was studied after intracerebral and corneal inoculation in newborn and adult ICR mice. ICP6 delta failed to replicate in brains of mice greater than or equal to 8 days old but exhibited significant virulence for newborn mice as a result of viral replication in the brains. The RR- and a thymidine kinase (TK)-deficient mutant of HSV-1 strain KOS could grow in eye tissues of adult ICR mice. Viral DNA of hrR3 was detected in brain tissues of intracerebrally infected mice or in the trigeminal ganglia of corneally infected mice greater than or equal to 50 days after infection, and infectious hrR3 could be recovered from these tissues by superinfection of the mice with wild-type HSV-2. These observations indicate that pathogenicity of RR- mutants in mice is highly dependent on the physiologic state of tissues infected and that RR- mutants have the ability to establish latency in nervous system tissues of mice by either the peripheral or intracerebral route. It was also demonstrated that the inability of the RR- mutants to invade the central nervous system was efficiently complemented by simultaneous infection with another defective virus, the TK- mutant of KOS.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1659596     DOI: 10.1093/infdis/164.6.1091

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  26 in total

Review 1.  Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates.

Authors:  Guido Wollmann; Koray Ozduman; Anthony N van den Pol
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

2.  Evaluation of a peptidomimetic ribonucleotide reductase inhibitor with a murine model of herpes simplex virus type 1 ocular disease.

Authors:  C R Brandt; B Spencer; P Imesch; M Garneau; R Déziel
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

3.  Noninvasive bioluminescence imaging of herpes simplex virus type 1 infection and therapy in living mice.

Authors:  Gary D Luker; J Patrick Bardill; Julie L Prior; Christina M Pica; David Piwnica-Worms; David A Leib
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

4.  The range and distribution of murine central nervous system cells infected with the gamma(1)34.5- mutant of herpes simplex virus 1.

Authors:  N S Markovitz; D Baunoch; B Roizman
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

5.  Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors.

Authors:  Ryuichi Kanai; Cecile Zaupa; Donatella Sgubin; Slawomir J Antoszczyk; Robert L Martuza; Hiroaki Wakimoto; Samuel D Rabkin
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

Review 6.  The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma-Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses.

Authors:  Russell Maxwell; Andrew S Luksik; Tomas Garzon-Muvdi; Michael Lim
Journal:  Curr Neurol Neurosci Rep       Date:  2017-06       Impact factor: 5.081

Review 7.  Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress.

Authors:  Balveen Kaur; E Antonio Chiocca; Timothy P Cripe
Journal:  Curr Pharm Biotechnol       Date:  2012-07       Impact factor: 2.837

8.  Recombinants are isolated at high frequency following in vivo mixed ocular infection with two avirulent herpes simplex virus type 1 strains.

Authors:  R L Kintner; R W Allan; C R Brandt
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

9.  Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide.

Authors:  Mark A Currier; Rebecca A Gillespie; Nancy M Sawtell; Yonatan Y Mahller; Greg Stroup; Margaret H Collins; Hirokazu Kambara; E Antonio Chiocca; Timothy P Cripe
Journal:  Mol Ther       Date:  2008-03-25       Impact factor: 11.454

10.  Topical treatment of infection with acyclovir-resistant mucocutaneous herpes simplex virus with the ribonucleotide reductase inhibitor 348U87 in combination with acyclovir.

Authors:  S Safrin; T Schacker; J Delehanty; E Hill; L Corey
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.